citalopram has been researched along with Coronary Artery Disease in 7 studies
Citalopram: A furancarbonitrile that is one of the serotonin uptake inhibitors used as an antidepressant. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from TARDIVE DYSKINESIA in preference to tricyclic antidepressants, which aggravate dyskinesia.
citalopram : A racemate comprising equimolar amounts of (R)-citalopram and its enantiomer, escitalopram. It is used as an antidepressant, although only escitalopram is active.
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile : A nitrile that is 1,3-dihydro-2-benzofuran-5-carbonitrile in which one of the hydrogens at position 1 is replaced by a p-fluorophenyl group, while the other is replaced by a 3-(dimethylamino)propyl group.
Coronary Artery Disease: Pathological processes of CORONARY ARTERIES that may derive from a congenital abnormality, atherosclerotic, or non-atherosclerotic cause.
| Excerpt | Relevance | Reference |
|---|---|---|
| "gov NCT02516332) will evaluate the efficacy of aerobic exercise and escitalopram for improving anxiety symptoms and reducing risk for adverse clinical events in anxious CHD patients." | 9.22 | Treatment of anxiety in patients with coronary heart disease: Rationale and design of the UNderstanding the benefits of exercise and escitalopram in anxious patients WIth coroNary heart Disease (UNWIND) randomized clinical trial. ( Ashworth, M; Babyak, MA; Blumenthal, JA; Davidson, J; Feger, BJ; Hinderliter, A; Hoffman, BM; Jiang, W; Kraus, WE; Mabe, SK; Sherwood, A; Smith, PJ; Watkins, LL, 2016) |
| "Citalopram was superior to placebo in reducing 12-week HAM-D scores (mean difference, 3." | 6.73 | Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy (CREATE) trial. ( Abramson, BL; Baker, B; Dorian, P; Frasure-Smith, N; Ghatavi, K; Guertin, MC; Koszycki, D; Laliberté, MA; Lespérance, F; Swenson, JR; van Zyl, LT, 2007) |
| "gov NCT02516332) will evaluate the efficacy of aerobic exercise and escitalopram for improving anxiety symptoms and reducing risk for adverse clinical events in anxious CHD patients." | 5.22 | Treatment of anxiety in patients with coronary heart disease: Rationale and design of the UNderstanding the benefits of exercise and escitalopram in anxious patients WIth coroNary heart Disease (UNWIND) randomized clinical trial. ( Ashworth, M; Babyak, MA; Blumenthal, JA; Davidson, J; Feger, BJ; Hinderliter, A; Hoffman, BM; Jiang, W; Kraus, WE; Mabe, SK; Sherwood, A; Smith, PJ; Watkins, LL, 2016) |
| "The CREATE trial reported that coronary artery disease (CAD) patients suffering from a first depression derived less benefit from citalopram relative to placebo than those with a recurrent depression." | 5.14 | First episode of major depressive disorder and vascular factors in coronary artery disease patients: Baseline characteristics and response to antidepressant treatment in the CREATE trial. ( Baker, B; Butler, G; Frasure-Smith, N; Habra, ME; Koszycki, D; Lespérance, F; Swenson, JR; van Zyl, LT, 2010) |
| "Citalopram was superior to placebo in reducing 12-week HAM-D scores (mean difference, 3." | 2.73 | Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy (CREATE) trial. ( Abramson, BL; Baker, B; Dorian, P; Frasure-Smith, N; Ghatavi, K; Guertin, MC; Koszycki, D; Laliberté, MA; Lespérance, F; Swenson, JR; van Zyl, LT, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (57.14) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alenezi, F | 1 |
| Brummett, BH | 1 |
| Boyle, SH | 1 |
| Samad, Z | 1 |
| Babyak, MA | 2 |
| Alzaeim, N | 1 |
| Wilson, J | 1 |
| Romano, MMD | 1 |
| Sun, JL | 1 |
| Ersboll, M | 1 |
| O'Connor, CM | 1 |
| Velazquez, EJ | 1 |
| Jiang, W | 2 |
| Blumenthal, JA | 1 |
| Feger, BJ | 1 |
| Smith, PJ | 1 |
| Watkins, LL | 1 |
| Davidson, J | 1 |
| Hoffman, BM | 1 |
| Ashworth, M | 1 |
| Mabe, SK | 1 |
| Kraus, WE | 1 |
| Hinderliter, A | 1 |
| Sherwood, A | 1 |
| Habra, ME | 1 |
| Baker, B | 2 |
| Frasure-Smith, N | 2 |
| Swenson, JR | 2 |
| Koszycki, D | 2 |
| Butler, G | 1 |
| van Zyl, LT | 2 |
| Lespérance, F | 2 |
| Laliberté, MA | 1 |
| Ghatavi, K | 1 |
| Abramson, BL | 1 |
| Dorian, P | 1 |
| Guertin, MC | 1 |
| Glassman, AH | 1 |
| Bigger, JT | 1 |
| Ziegelstein, RC | 1 |
| Dornelas, EA | 1 |
| Burg, MM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Exercise and Pharmacotherapy for Anxiety in Cardiac Patients[NCT02516332] | 128 participants (Actual) | Interventional | 2015-12-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
To assess baroreflex sensitivity (BRS), beat-by-beat systolic blood pressure (SBP) and heart rate (HR) were collected using the Nexfin noninvasive BP monitor (Bmeye, Amsterdam, Netherlands). BRS was estimated from the magnitude of the transfer function relating R-R interval oscillations to SBP oscillations across the 0.07 to 0.1299 Hz, or low frequency band. (NCT02516332)
Timeframe: Baseline, 3 months
| Intervention | ms/mm Hg (Least Squares Mean) |
|---|---|
| Supervised Aerobic Exercise | 1.2 |
| Lexapro | 1.3 |
| Placebo | 1.5 |
To quantify heart rate variability (HRV), an electrocardiogram was recorded for 24-hours using the 3-channel DigiTrak XT Holter recorder (Philips Healthcare, Andover, Massachusetts). Electrocardiographic data were downloaded and edited using the Philips Zymed Holter analysis software (2010 Plus/1810 series) and HRV was estimated from the standard deviation of the normal-to-normal R-R intervals (SDNN). (NCT02516332)
Timeframe: Baseline, 3 months
| Intervention | msec (Least Squares Mean) |
|---|---|
| Supervised Aerobic Exercise | -0.3 |
| Lexapro | -8.7 |
| Placebo | -1.1 |
The Hospital Anxiety and Depression Scale, Anxiety, is a 7-item subscale with scores ranging from 0-21, with higher scores indicating more anxiety. (NCT02516332)
Timeframe: Baseline, 3 months
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Supervised Aerobic Exercise | -3.9 |
| Lexapro | -5.7 |
| Placebo | -3.5 |
High-sensitivity C-reactive protein was quantified by ELISA (LabCorp). Values >10 mg/L were truncated at 10 to account for acute inflammatory processes that may have skewed the distribution of this blood marker. (NCT02516332)
Timeframe: Baseline, 3 months
| Intervention | ug/ml (Least Squares Mean) |
|---|---|
| Supervised Aerobic Exercise | -0.2 |
| Lexapro | 0.1 |
| Placebo | -0.3 |
Urinary catecholamines, an index of sympathetic nervous system (SNS) activity, served as a biomarker of anxiety. Urinary concentrations of epinephrine (EPI) and norepinephrine (NE) were determined by high-pressure liquid chromatography (HPLC) with electrochemical detection (LabCorp). A composite 24-hr catecholamines z-score is presented. The z-score is the raw score minus the population mean, divided by the population standard deviation. A Z-score of 0 is equal to the mean. Negative numbers indicate values lower than the mean and positive numbers indicate values higher than the mean. (NCT02516332)
Timeframe: Baseline, 3 months
| Intervention | z-score (Least Squares Mean) |
|---|---|
| Supervised Aerobic Exercise | 0.05 |
| Lexapro | -0.24 |
| Placebo | 0.36 |
Endothelial function, assessed by Flow-Mediated Dilation (FMD), was determined from longitudinal B-mode ultrasound images of the brachial artery. Images were obtained using an Acuson (Mountain View, California) Aspen ultrasound platform with an 11-MHz linear-array transducer after 10 min of supine relaxation and during reactive hyperemia, induced by the inflation of a forearm pneumatic occlusion cuff to suprasystolic pressure (about 200 mm Hg) and subsequent deflation after 5 min. FMD was defined as the maximum percentage change in arterial diameter relative to resting baseline from 10 to 120 s after deflation of the occlusion cuff. (NCT02516332)
Timeframe: Baseline, 3 months
| Intervention | percentage of dilation (Least Squares Mean) |
|---|---|
| Supervised Aerobic Exercise | 0.7 |
| Lexapro | 0.5 |
| Placebo | 0.5 |
Lipids were obtained from fasting blood samples and assays were measured enzymatically (LabCorp). (NCT02516332)
Timeframe: Baseline, 3 months
| Intervention | mg/dL (Least Squares Mean) | ||
|---|---|---|---|
| Total Cholesterol | LDL | HDL | |
| Lexapro | -15.3 | -9.8 | 3.4 |
| Placebo | -31.6 | -19.3 | 7.2 |
| Supervised Aerobic Exercise | -28.2 | -18.6 | 6.3 |
4 trials available for citalopram and Coronary Artery Disease
3 other studies available for citalopram and Coronary Artery Disease
| Article | Year |
|---|---|
Antidepressants in coronary heart disease: SSRIs reduce depression, but do they save lives?
Topics: Citalopram; Coronary Artery Disease; Depressive Disorder, Major; Humans; Psychotherapy, Brief; Selec | 2007 |
Treatment of depression in patients with coronary artery disease.
Topics: Aged; Citalopram; Coronary Artery Disease; Depressive Disorder, Major; Humans; Middle Aged; Psychoth | 2007 |
Treatment of depression in patients with coronary artery disease.
Topics: Citalopram; Coronary Artery Disease; Depressive Disorder, Major; Humans; Psychotherapy, Brief; Selec | 2007 |